Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial
Navin Pinto(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital), Araz Marachelian(University of Southern California), Joel M. Reid(Children's Hospital of Philadelphia), Min H. Kang(Texas Tech University), Agne Taraseviciute(Seattle Children's Hospital), Meredith S. Irwin(University of Toronto), C. Patrick Reynolds(St. Jude Children's Research Hospital), Margaret E. Macy(Children's Hospital Colorado), Denice Tsao‐Wei(Children's Hospital of Los Angeles), Susan Groshen(USC Norris Comprehensive Cancer Center), Scott J. Diede(Merck & Co., Inc., Rahway, NJ, USA (United States)), Judith G. Villablanca(University of Southern California), Julia Glade Bender(Columbia University Irving Medical Center), Steven G. DuBois(University of California, San Francisco), Daphne A. Haas‐Kogan(Brigham and Women's Hospital), Katherine K. Matthay(University of California System)
Cited by 39
Related Papers
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
|Journal of Clinical Oncology|1999|670
Artificial intelligence in radiation oncology
|Nature Reviews Clinical Oncology|2020|399
Pediatric high-grade glioma: biologically and clinically in need of new thinking
|Neuro-Oncology|2016|365